Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 16914735
Shi CS, et al. (2006) The mitogen-activated protein kinase kinase kinase kinase GCKR positively regulates canonical and noncanonical Wnt signaling in B lymphocytes. Mol Cell Biol 26, 6511-21 16914735
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S9-p - GSK3B (human)
Modsite: SGRPRttsFAEsCkP SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S9‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, B cell lymphoma, Burkitt's lymphoma
Relevant cell lines - cell types - tissues:  293 (epithelial), B lymphocyte, BJAB (B lymphocyte), Raji (B lymphocyte), WEHI-231 (B lymphocyte)
Cellular systems studied:  cell lines, primary cells
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE KHS1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE KHS1 (human) microscopy-colocalization, pharmacological activator of upstream enzyme, transfection of inactive enzyme, siRNA inhibition of enzyme, phospho-antibody, transfection of wild-type enzyme, co-immunoprecipitation, genetic knockout/knockin of upstream enzyme

T178-p - JNK1 (human)
Modsite: GLARTAGtsFMMtPy SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T178‑p, JNK1 iso2 (human): T178‑p, JNK1 iso3 (human): T178‑p, JNK1 (mouse): T178‑p, JNK1 (rat): T178‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, B cell lymphoma, Burkitt's lymphoma
Relevant cell lines - cell types - tissues:  293 (epithelial), B lymphocyte, BJAB (B lymphocyte), Raji (B lymphocyte), WEHI-231 (B lymphocyte)
Cellular systems studied:  cell lines, primary cells
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Wnt3a increase
sFRP-1 Wnt3a inhibit treatment-induced increase
Wnt3a KHS1 (human) increase
Wnt3a APC (human) increase
Wnt3a ARHGEF4 (mouse) increase

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, B cell lymphoma, Burkitt's lymphoma
Relevant cell lines - cell types - tissues:  293 (epithelial), B lymphocyte, BJAB (B lymphocyte), Raji (B lymphocyte), WEHI-231 (B lymphocyte)
Cellular systems studied:  cell lines, primary cells
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Wnt3a increase
sFRP-1 Wnt3a inhibit treatment-induced increase
Wnt3a KHS1 (human) increase
Wnt3a APC (human) increase
Wnt3a ARHGEF4 (mouse) increase

S9-p - GSK3B (mouse)
Modsite: SGRPRttsFAEsCKP SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S9‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, B cell lymphoma, Burkitt's lymphoma
Relevant cell lines - cell types - tissues:  293 (epithelial), B lymphocyte, BJAB (B lymphocyte), Raji (B lymphocyte), WEHI-231 (B lymphocyte)
Cellular systems studied:  cell lines, primary cells
Species studied:  human, mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE KHS1 (human) microscopy-colocalization, pharmacological activator of upstream enzyme, transfection of inactive enzyme, siRNA inhibition of enzyme, phospho-antibody, transfection of wild-type enzyme, co-immunoprecipitation, genetic knockout/knockin of upstream enzyme

T178-p - JNK1 (mouse)
Modsite: GLARTAGtsFMMtPy SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T178‑p, JNK1 iso2 (human): T178‑p, JNK1 iso3 (human): T178‑p, JNK1 (mouse): T178‑p, JNK1 (rat): T178‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, B cell lymphoma, Burkitt's lymphoma
Relevant cell lines - cell types - tissues:  293 (epithelial), B lymphocyte, BJAB (B lymphocyte), Raji (B lymphocyte), WEHI-231 (B lymphocyte)
Cellular systems studied:  cell lines, primary cells
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Wnt3a increase
sFRP-1 Wnt3a inhibit treatment-induced increase
Wnt3a KHS1 (human) increase
Wnt3a APC (human) increase
Wnt3a ARHGEF4 (mouse) increase

T183-p - JNK1 (mouse)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, B cell lymphoma, Burkitt's lymphoma
Relevant cell lines - cell types - tissues:  293 (epithelial), B lymphocyte, BJAB (B lymphocyte), Raji (B lymphocyte), WEHI-231 (B lymphocyte)
Cellular systems studied:  cell lines, primary cells
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Wnt3a increase
sFRP-1 Wnt3a inhibit treatment-induced increase
Wnt3a KHS1 (human) increase
Wnt3a APC (human) increase
Wnt3a ARHGEF4 (mouse) increase